Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 4 of 34« First...23456...102030...Last »

Merck Reveals Recent U.S. Drug Price Increases

As drug pricing continues to be a concern for the public and the new presidential administration, Merck pulled back the curtain on its U.S. pricing practices.

Read More »

Tecentriq eroding Opdivo market share

Roche’s cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb, but is making up lost ground.

Read More »

Merck CEO sees Keytruda in pole position in cancer race

Merck & Co.’s Keytruda cancer drug is in an increasingly strong position in a fiercely competitive market, the company’s CEO said.

Read More »

Regeneron CEO: Amgen not putting patients first

Regeneron CEO Len Schleifer ripped into Amgen for its insistence on blocking sales of a rival cholesterol drug during the appeals process in a patent infringement case.

Read More »

Benefits of new cancer drugs vary widely

Drugs recently approved around the world to fight cancer increased patients’ overall survival, but benefits vary depending on the drug, a new study shows.

Read More »

Democrats lean on drug pricing as ACA repeal looms

Democrats are showing little interest in cooperating with the Republicans who control Congress on legislation to dismantle the Obamacare health insurance law, but some are signaling a willingness to collaborate on action to curb rising drug prices.

Read More »

Express Scripts: No let-up in drug pricing chatter

Express Scripts Holding Co. – the largest pharmacy benefit manager in the United States – signaled that scrutiny into drug pricing is not going away.

Read More »

New diabetes guidelines imminent, Jardiance sales may surge

Two leading U.S. medical societies are poised to issue new diabetes treatment guidelines that are expected to reflect the lifesaving cardiovascular effects of Eli Lilly’s Jardiance.

Read More »

Global prescription drug spend seen at $1.5 trillion in 2021: report

Global spending on prescription medicines will reach nearly $1.5 trillion by 2021, although the annual rate of growth will decrease from recent years, according to a forecast by Quintiles IMS Holding.

Read More »

Healthcare Agency Roundtable 2016

Management from 2016 Manny Award winners and finalists weigh in on various industry topics presented to them by Med Ad News.

Read More »

Novo, Sanofi face off with new diabetes drugs

Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes, sparking a fresh battle for sales in a fiercely competitive market.

Read More »

NICE U-Turns, Backs Approval of Roche’s Perjeta

The National Institute for Clinical Excellence has finally given backing for the NHS’ approval of Perjeta for human epidermal growth factor receptor 2-positive breast cancer.

Read More »

No early win for cholesterol drug Praluent

Sanofi and Regeneron will continue a large clinical outcomes study for the injectable cholesterol-lowering drug Praluent, confounding hopes of an early win.

Read More »

How Pharma Can Continue Moving Beyond the Pill

It’s important for the pharma industry to take a closer look at the benefits of going beyond the pill and leveraging technology to deliver better care resulting in better patient outcomes and potential savings to the overall health system.

Read More »

U.S. watchdog told Medicare, Medicaid that EpiPen was misclassified in 2009: senator

The internal watchdog at the U.S. Department of Health and Human Services warned the office tasked with administering federal health insurance programs that Mylan NV’s EpiPen was improperly classified as a generic drug in 2009, Senator Charles Grassley said.

Read More »

EpiPen rival plans on U.S. market return in 2017

Privately held drugmaker Kaleo Inc. announced plans for a U.S. relaunch of its Auvi-Q injector for life-threatening allergic reactions in the first half of 2017.

Read More »

UK to ‘fast track’ most cost-effective new drugs

Britain’s healthcare cost agency NICE plans to fast-track its recommendations for the most cost-effective new drugs.

Read More »

Most U.S. dermatologists receive industry money

Nearly three-quarters of U.S. dermatologists received payments worth a collective $34 million from drug companies in 2014, according to a new analysis of a public database.

Read More »

Merrimack CEO Resigns, Company Slashes Jobs

Robert Mulroy, CEO of Merrimack Pharmaceuticals, has resigned his position as part of a corporate restructuring move that will result in a 22 percent workforce reduction.

Read More »

Regeneron’s Eylea combo therapy fails study

Regeneron Pharmaceuticals’ combo therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet AMD.

Read More »

Page 4 of 34« First...23456...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation